HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $139 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Krystal Biotech (NASDAQ:KRYS) and maintained a price target of $139.
August 07, 2023 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $139.
The reiteration of the 'Buy' rating and maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100